CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and its co-plaintiffs announced that they are filing today a petition for an en banc rehearing of an April decision by the U.S. Court of Appeals for the Federal Circuit (CAFC) in its patent infringement case against Eli Lilly and Company. That decision overturned two lower court rulings relating to the alleged infringement by Lilly of U.S. Patent No. 6,410,516 (the ‘516 patent) licensed to ARIAD by Harvard, MIT and the Whitehead Institute (collectively, “the co-plaintiffs”). If the petition is granted, the case would be reheard by all twelve judges of the CAFC reassessing the validity of the asserted patent claims.
